Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Phase 2 N=32 Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Prostate Cancer
Primary: Duration of the First "Off-treatment" Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind. — 39 Weeks
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
Phase 3 N=790 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Primary: Overall Survival — 57.6; 44.0 months — p=0.0003
Early Phase 1 N=27 IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
Phase 2 N=12 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
Prostate Cancer Metastatic
Primary: Number of Participants With Prostate Specific Antigen (PSA) >=50 Response — 5 Participants
Phase 1 N=41 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
N/A N=39 Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Percent Change of 17-OHP Levels From Baseline — 67; 140 percent change
Phase 2 N=79 Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
Metastatic Cancer · Prostate Cancer
Primary: Progression Free Survival (PFS) — 12.9; 18.5 Months
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 2 N=44 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Stable Disease at 4 Months. — 2; 5 participants